DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world. Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits. DiogenX is headquartered in Marseille, with labs in Nice (France).
| Website | http://www.diogenx.com/ |
| Employees | 25 (17 on RocketReach) |
| Founded | 2020 |
| Technologies |
JavaScript
,
HTML
,
PHP
+14 more
(view full list)
|
| Industry | Biotechnology, Drug Discovery |
| Keywords | Diabetes Treatment, Biologics, Diabetes Research, Therapeutics, New Therapeutics, Preclinical, Blood Sugar, Drug Discovery, Clinical Trials, Biotechnology, Drug Development, Glucose Control, Pharmaceutical, Medical Research, Biotech, Diabetes Management, Life Sciences, Insulin |
| Competitors | Roche, Novartis, Merck AH, Sanofi, GSK, AstraZeneca, Boehringer Ingelheim, Pfizer, Amgen, Lilly India +45 more (view full list) |
Looking for a particular DiogenX employee's phone or email?
Benjamin Charles is the Chief Executive Officer - Co-founder of DiogenX.
17 people are employed at DiogenX.
DiogenX is based in Marseille, Provence-Alpes-Côte d'Azur.